The mycorrhizal status of Phragmites australis in several polluted soils and sediments of an industrialised region of Northern Portugal

Roots of Phragmites australis from three polluted soils and sediments (a periodically flooded stream bank containing organic pollutants, a high-pH drying sedimentation pond and an acidic, periodically flooded sand polluted by industrial effluents) were sampled over a 1-year cycle of plant growth to assess the degree of colonisation by arbuscular mycorrhizal fungi (AMF). At the dry sedimentation pond, root samples of Juncus effusus and Salix atrocinerea were also taken to assess the presence of AMF throughout the year. Root colonisation was low (<5% root length colonised) but arbuscule presence peaked in P. australis during the spring and autumn prior to flowering. These changes in arbuscule abundance were also seen in a parallel greenhouse trial using seed taken from one of the sites. Roots of J. effusus contained mainly vesicular colonisation but arbuscule activity peaked during the winter months (December–March). S. atrocinerea roots were found to be ectomycorrhizal throughout the year but the fine feeder roots were colonised by AMF. The results confirm that semi-aquatics, like P. australis, can become arbuscular mycorrhizal but that this status changes during the year depending on soil moisture content and plant phenology. The influence of AMF in these polluted soils is uncertain but the potential exists to establish a more diverse plant ecosystem during the landscaping of these areas (phytostabilisation) by management of adapted plant and AMF ecotypes

Generation of three-qubit entangled states using coupled multi-quantum dots

We discuss a mechanism for generating a maximum entangled state (GHZ) in a coupled quantum dots system, based on analytical techniques. The reliable generation of such states is crucial for implementing solid-state based quantum information schemes. The signature originates from a remarkably weak field pulse or a far off-resonance effects which could be implemented using technology that is currently being developed. The results are illustrated with an application to a specific wide-gap semiconductor quantum dots system, like Zinc Selenide (ZnSe) based quantum dots.Comment: 8 pages, 2 figure

An artificial immune system for fuzzy-rule induction in data mining

This work proposes a classification-rule discovery algorithm integrating artificial immune systems and fuzzy systems. The algorithm consists of two parts: a sequential covering procedure and a rule evolution procedure. Each antibody (candidate solution) corresponds to a classification rule. The classification of new examples (antigens) considers not only the fitness of a fuzzy rule based on the entire training set, but also the affinity between the rule and the new example. This affinity must be greater than a threshold in order for the fuzzy rule to be activated, and it is proposed an adaptive procedure for computing this threshold for each rule. This paper reports results for the proposed algorithm in several data sets. Results are analyzed with respect to both predictive accuracy and rule set simplicity, and are compared with C4.5rules, a very popular data mining algorithm

Characterizing top gated bilayer graphene interaction with its environment by Raman spectroscopy

In this work we study the behavior of the optical phonon modes in bilayer graphene devices by applying top gate voltage, using Raman scattering. We observe the splitting of the Raman G band as we tune the Fermi level of the sample, which is explained in terms of mixing of the Raman (Eg) and infrared (Eu) phonon modes, due to different doping in the two layers. We theoretically analyze our data in terms of the bilayer graphene phonon self-energy which includes non-homogeneous charge carrier doping between the graphene layers. We show that the comparison between the experiment and theoretical model not only gives information about the total charge concentration in the bilayer graphene device, but also allows to separately quantify the amount of unintentional charge coming from the top and the bottom of the system, and therefore to characterize the interaction of bilayer graphene with its surrounding environment

Antiviral and cytotoxic activity of different plant parts of banana (Musa spp.)

Open Access Journal; Published online: 15 May 2020Chikungunya and yellow fever virus cause vector-borne viral diseases in humans. There is currently no specific antiviral drug for either of these diseases. Banana plants are used in traditional medicine for treating viral diseases such as measles and chickenpox. Therefore, we tested selected banana cultivars for their antiviral but also cytotoxic properties. Different parts such as leaf, pseudostem and corm, collected separately and extracted with four different solvents (hexane, acetone, ethanol, and water), were tested for in vitro antiviral activity against Chikungunya virus (CHIKV), enterovirus 71 (EV71), and yellow fever virus (YFV). Extracts prepared with acetone and ethanol from leaf parts of several cultivars exhibited strong (EC50 around 10 μg/mL) anti-CHIKV activity. Interestingly, none of the banana plant extracts (concentration 1–100 µg/mL) were active against EV71. Activity against YFV was restricted to two cultivars: Namwa Khom–Pseudostem–Ethanol (5.9 ± 5.4), Namwa Khom–Corm–Ethanol (0.79 ± 0.1) and Fougamou–Corm–Acetone (2.5 ± 1.5). In most cases, the cytotoxic activity of the extracts was generally 5- to 10-fold lower than the antiviral activity, suggesting a reasonable therapeutic window

Antifungals In Eye Infections: Drugs And Routes Of Administration

Treatment of fungal eye infections represents a challenge to the ophthalmology practice. For an adequate therapeutic response, besides correct drug choice, it is necessary an effectively administration. This script gathers information about the major antifungal drugs used in eye infections, their concentrations and main administration routes.722132141Leber, T.H., Keratomycosis aspergillina als ursache von hypopyonkeratites (1879) Graefes Ach Clin Exp Ophthalmol, 25, pp. 285-301Alfonso, E.C.G.A., Miller, D., Fungal keratitis (2011) Cornea: fundamentals, diagnosis and management, , In: Krachmer JH, Mannis MJ, Holland EJ, editors.3rd ed. New York: Mosby ElsevierJones, D., Diagnosis and management of fungal keratitis Duane's clinical ophthalmology, p. 2004. , In: Tasman W, Jaeger EA, editors.Philadelphia: Lippincott Williams & WilkinsBennett, J., Agentes antimicrobianos, agentes antifúngicos (2007) As bases farmacológicas da terapêutica, pp. 1103-1117. , In: Brunton L, editor Goodman & Gilman:11a ed. Rio de Janeiro: McGraw-HillReddy, P.R., Reddy, P.S., Reddy, A.R., Saboo, N.K., A comparative evaluation of Nystatin, Amphotericin-B and Miconazole in keratomycosis (1982) Indian J Ophthalmol, 30 (4), pp. 249-250Oliveira, P.R., Resende, S.M., Oliveira, F.C., Oliveira, A.C., Ceratite fúngica (2001) Arq Bras Oftalmol, 64 (1), pp. 75-79Filippin, F.B., Souza, L.C., Eficiência terapêutica das formulações lipídicas de anfotericina B (2006) RBCF Rev Bras Ciênc Farm, 42 (2), pp. 167-194Martinez, R., Atualização no uso de agentes antifúngicos (2006) J Bras Pneumol, 32 (5), pp. 449-460Gallis, H.A., Drew, R.H., Pickard, W.W., Amphotericin B: 30 years of clinical experience (1990) Rev Infect Dis, 12 (2), pp. 308-329Kaur, I.P., Rana, C., Singh, H., Development of effective ocular preparations of antifungal agents (2008) J Ocul Pharmacol Ther, 24 (5), pp. 481-493. , ReviewKhoo, S.H., Bond, J., Denning, D.W., Administering amphotericin B-a practical approach (1994) J Antimicrob Chemother, 33 (2), pp. 203-213Mora-Duarte, J., Betts, R., Rotstein, C., Colombo, A.L., Thompson-Moya, L., Smietana, J., Lupinacci, R., Perfect, J., Caspofungin Invasive Candidiasis Study Group.Comparison of caspofungin and amphotericin B for invasive candidiasis (2002) N Engl J Med, 347 (25), pp. 2020- 9. , Comment in N Engl J Med. 2002;347(25):2070-2. ACP J Club. 2003;139(1):15. N Engl J Med. 2003;348(13):1287-8author reply 1287-8Shirley, S.F., Little, J.R., Immunopotentiating effects of amphotericin B (1979) I.Enhanced contact sensitivity in mice. J Immunol., 123 (6), pp. 2878-2882Shirley, S.F., Little, J.R., Immunopotentiating effects of amphotericin B (1979) II Enhanced in vitro proliferative responses of murine lymphocytes. J Immunol., 123 (6), pp. 2883-2889Green, W.R., Bennett, J.E., Goos, R.D., Ocular penetration of amphotericin B: a report of laboratory studies and a case report of postsurgical cephalosporium endophthalmitis (1965) Arch Ophthalmol, 73, pp. 769-775Goldblum, D., Frueh, B.E., Zimmerli, S., Böhnke, M., Treatment of postkeratitis fusarium endophthalmitis with amphotericin B lipid complex (2000) Cornea, 19 (6), pp. 853-856O'Day, D.M., Head, W.S., Robinson, R.D., Stern, W.H., Freeman, J.M., Intraocular penetration of systemically administered antifungal agents (1985) Curr Eye Res, 4 (2), pp. 131-134. , Erratum in: Curr Eye Res 1986;5(7):547Qu, L., Li, L., Xie, H., Corneal and aqueous humor concentrations of amphotericin B using three different routes of administration in a rabbit model (2010) Ophthalmic Res, 43 (3), pp. 153-158Pleyer, U., Grammer, J., Pleyer, J.H., Kosmidis, P., Friess, D., Schmidt, K.H., Thiel, H.J., Studies with local administration of liposome incorporated amphotericin (1995) Amphotericin B-bioavailability in the cornea Ophthalmologe, 92 (4), pp. 469-475. , GermanO'Day, D.M., Head, W.S., Robinson, R.D., Clanton, J.A., Corneal penetration of topical amphotericin B and natamycin (1986) Curr Eye Res, 5 (11), pp. 877-882O'Day, D.M., Ray, W.A., Head, W.S., Robinson, R.D., Influence of the corneal epithelium on the efficacy of topical antifungal agents (1984) Invest Ophthalmol Vis Sci, 25 (7), pp. 855-859Hirose, H., Terasaki, H., Awaya, S., Yasuma, T., Treatment of fungal corneal ulcers with amphotericin B ointment (1997) Am J Ophthalmol, 124 (6), pp. 836-838Wood, T.O., Williford, W., Treatmen of keratomycosis with amphotericin B 015% (1976) Am J Ophthalmol., 81 (6), pp. 847-849O'Day, D.M., Selection of appropriate antifungal therapy (1987) Cornea, 6 (4), pp. 238-245. , ReviewO'Day, D.M., Ray, W.A., Robinson, R.D., Head, W.S., Williams, T.E., Differences in response in vivo to amphotericin B among Candida albicans strains (1991) Invest Ophthalmol Vis Sci, 32 (5), pp. 1569-1572Garcia-Valenzuela, E., Song, C.D., Intracorneal injection of amphothericin B for recurrent fungal keratitis and endophthalmitis (2005) Arch Ophthalmol, 123 (12), pp. 1721-1723Kermani, N.K., Aggarwal, S.P., Isolated post-operative Aspergillus niger endophthalmitis (2000) Eye (Lond), 14 (PART 1), pp. 114-116Yoon, K.C., Jeong, I.Y., Im, S.K., Chae, H.J., Yang, S.Y., Therapeutic effect of intracameral amphotericin B injection in the treatment of fungal keratitis (2007) Cornea, 26 (7), pp. 814-818Kaushik, S., Ram, J., Brar, G.S., Jain, A.K., Chakraborti, A., Gupta, A., Intracameral amphotericin B: initial experience in severe keratomycosis (2001) Cornea, 20 (7), pp. 715-719Kuriakose, T., Kothari, M., Paul, P., Jacob, P., Thomas, R., Intracameral amphotericin B injection in the management of deep keratomycosis (2002) Cornea, 21 (7), pp. 653-656Yilmaz, S., Ture, M., Maden, A., Efficacy of intracameral amphotericin B injection in the management of refractory keratomycosis and endophthalmitis (2007) Cornea, 26 (4), pp. 398-402Perraut, L.E., Perraut, L.E., Bleiman, B., Lyons, J., Successful treatment of Candida albicans endophthalmitis with intravitreal amphotericin B (1981) Arch Ophthalmol, 99 (9), pp. 1565-1567Serracarbassa, P.D., Peyman, G.A., Liang, C., Calixto, N., Nair, M.G., Toxicity and efficacy of intravitreal injection of spartanamicin B in the treatment of Candida endophthalmitis (1998) Int Ophthalmol, 22 (1), pp. 53-58Mascaro, V.L.D.M., Höfling-Lima, A.L., Gompertz, O.F., Yu, M.C.Z., Matta, D.A., Colombo, A.L., Antifungal susceptibility testing of yeast isolated from corneal infections (2003) Arq Bras Oftalmol, 66 (5), pp. 647-652Mattia, A., Cerniglia, C., Baines, J., Safety evaluation of certain food additives and contaminants Natamycin, , http://www.inchem.org/documents/jecfa/jecmono/v48je06.htm, Pimaricin WHO Food Additives Series: 48.Available fromTu, E.Y., McCartney, D.L., Beatty, R.F., Springer, K.L., Levy, J., Edward, D., Successful treatment of resistant ocular fusariosis with posaconazole (2007) Am J Ophthalmol, 143 (2), pp. 222-227. , SCH-56592Jones, D.B., Sexton, R., Rebell, G., Mycotic keratitis in South Florida: a review of thirty-nine cases (1970) Trans Ophthalmol Soc U K, 89, pp. 781-797Panda, A., Sharma, N., Das, G., Kumar, N., Satpathy, G., Mycotic keratitis in children: epidemiologic and microbiologic evaluation (1997) Cornea, 16 (3), pp. 295-299Rosa, R.H., Miller, D., Alfonso, E.C., The changing spectrum of fungal keratitis in south Florida (1994) Ophthalmology, 101 (6), pp. 1005-1013Oliveira, L.A., Takata, T.T., Shiguematsu, A.I., Júnior, M.L.A., Gompertz, O.F., Sousa, L.B., Mannis, M.J., Effect of topical 0.5% povidone-iodine compared to 5% natamycin in fungal keratitis caused by Fusarium solani in a rabbit model: a pilot study (2008) Arq Bras Oftalmol, 71 (6), pp. 860-864Prajna, N.V., Mascarenhas, J., Krishnan, T., Reddy, P.R., Prajna, L., Srinivasan, M., Comparison of natamycin and voriconazole for the treatment of fungal keratitis (2010) Arch Ophthalmol, 128 (6), pp. 672-678. , Comment in Arch Ophthalmol. 2011;129(6):814author reply 814-5Prajna, N.V., John, R.K., Nirmalan, P.K., Lalitha, P., Srinivasan, M., A randomised clinical trial comparing 2% econazole and 5% natamycin for the treatment of fungal keratitis (2003) Br J Ophthalmol, 87 (10), pp. 1235-1237Dursun, D., Fernandez, V., Miller, D., Alfonso, E.C., Advanced fusarium keratitis progressing to endophthalmitis (2003) Cornea, 22 (4), pp. 300-303Tanure, M.A., Cohen, E.J., Sudesh, S., Rapuano, C.J., Laibson, P.R., Spectrum of fungal keratitis at Wills Eye Hospital, Philadelphia, Pennsylvania (2000) Cornea, 19 (3), pp. 307-312Kalavathy, C.M., Parmar, P., Kaliamurthy, J., Philip, V.R., Ramalingam, M.D., Jesudasan, C.A., Thomas, P.A., Comparison of topical itraconazole 1% with topical natamycin 5% for the treatment of filamentous fungal keratitis (2005) Cornea, 24 (4), pp. 449-452Klont, R.R., Eggink, C.A., Rijs, A.J., Wesseling, P., Verweij, P.E., Successful treatment of Fusarium keratitis with cornea transplantation and topical and systemic voriconazole (2005) Clin Infect Dis, 40 (12), pp. e110-2Lalitha, P., Shapiro, B.L., Srinivasan, M., Prajna, N.V., Acharya, N.R., Fothergill, A.W., Antimicrobial susceptibility of Fusarium, Aspergillus, and other filamentous fungi isolated from keratitis (2007) Arch Ophthalmol, 125 (6), pp. 789-793Li, L., Wang, Z., Li, R., Luo, S., Sun, X., In vitro evaluation of combination antifungal activity against Fusarium species isolated from ocular tissues of keratomycosis patients (2008) Am J Ophthalmol, 146 (5), pp. 724-728Xuguang, S., Zhixin, W., Zhiqun, W., Shiyun, L., Ran, L., Ocular fungal isolates and antifungal susceptibility in northern China (2007) Am J Ophthalmol, 143 (1), pp. 131-133Pearce, J.W., Giuliano, E.A., Moore, C.P., In vitro susceptibility patterns of Aspergillus and Fusarium species isolated from equine ulcerative keratomycosis cases in the midwestern and southern United States with inclusion of the new antifungal agent voriconazole (2009) Vet Ophthalmol, 12 (5), pp. 318-324Jones, D.B., Forster, F.K., Rebell, G., Fusarium solani keratitis treated with natamycin (pimaricin): eighteen consecutive cases (1972) Arch Ophthalmol, 88 (2), pp. 147-154Polack, F.M., Kaufman, H.E., Newmark, E., Keratomycosis.Medical and surgical treatment (1971) Arch Ophthalmol, 85 (4), pp. 410-416Amaral, V.C.S., Junior, N.G.P., Ketoconazole- and fluconazole-induced embryotoxicity and skeletal anomalies in wistar rats: a comparative study (2008) Braz Arch Biol Technol, 51 (6), pp. 1153-1161Sawyer, P.R., Brogden, R.N., Pinder, R.M., Speight, T.M., Avery, G.S., Miconazole: a review of its antifungal activity and therapeutic efficacy (1975) Drugs, 9 (6), pp. 406-423Coley, K.C., Crain, J.L., Miconazole-induced fatal dysrhythmia (1997) Pharmacotherapy, 17 (2), pp. 379-382Barasch, A., Griffin, A.V., Miconazole revisited: new evidence of antifungal efficacy from laboratory and clinical trials (2008) Future Microbiol, 3 (3), pp. 265-269Fothergill, A.W., Miconazole: a historical perspective (2006) Expert Rev Anti Infect Ther, 4 (2), pp. 171-175Kobayashi, D., Kondo, K., Uehara, N., Otokozawa, S., Tsuji, N., Yagihashi, A., Watanabe, N., Endogenous reactive oxygen species is an important mediator of miconazole antifungal effect (2002) Antimicrob Agents Chemother, 46 (10), pp. 3113-3117Thevissen, K., Ayscough, K.R., Aerts, A.M., Du, W., De Brucker, K., Meert, E.M., Miconazole induces changes in actin cytoskeleton prior to reactive oxygen species induction in yeast (2007) J Biol Chem, 282 (30), pp. 21592-7Sud, I.J., Feingold, D.S., Mechanisms of action of the antimycotic imidazoles (1981) J Invest Dermatol, 76 (6), pp. 438-441Foster, C.S., Stefanyszyn, M., Intraocular penetration of miconazole in rabbits (1979) Arch Ophthalmol, 97 (9), pp. 1703-1706Mohan, M., Panda, A., Gupta, S.K., Management of human keratomycosis with miconazole (1989) Aust N Z J Ophthalmol, 17 (3), pp. 295-297Fitzsimons, R., Peters, A.L., Miconazole and ketoconazole as a satisfactory first-line treatment for keratomycosis (1986) Am J Ophthalmol, 101 (5), pp. 605-608Gupta, S.K., Efficacy of miconazole in experimental keratomycosis (1986) Aust N Z J Ophthalmol, 14 (4), pp. 373-376Foster, C.S., Miconazole therapy for keratomycosis (1981) Am J Ophthalmol, 91 (5), pp. 622-629Ishibashi, Y., Kaufman, H.E., The effects of subconjunctival miconazole in the treatment of experimental Candida keratitis in rabbits (1985) Arch Ophthalmol, 103 (10), pp. 1570-1573Thomas, P.A., Current perspectives on ophthalmic mycoses (2003) Clin Microbiol Rev, 16 (4), pp. 730-797Uchida, K., Abe, S., Yamaguchi, H., The postantifungal effect (PAFE) of itraconazole, in comparison with those of miconazole and fluconazole, on Candida Species (2006) Microbiol Immunol, 50 (9), pp. 679-685Heel, R.C., Brogden, R.N., Speight, T.M., Avery, G.S., Econazole: a review of its antifungal activity and therapeutic efficacy (1978) Drugs, 16 (3), pp. 177-201Mahashabde, S., Nahata, M.C., Shrivastava, U., A comparative study of anti-fungal drugs in mycotic corneal ulcer (1987) Indian J Ophthalmol, 35 (5-6), pp. 149-152Ishibashi, Y., Oral ketoconazole therapy for keratomycosis (1983) Am J Ophthalmol, 95 (3), pp. 342-345Thomas, P.A., Kalavathy, C.M., Abraham, D.J., Rajasekaran, J., Oral ketoconazole in Keratomycosis (1987) Indian J Ophthalmol, 35 (4), pp. 197-203Ishibashi, Y., Miconazole and ketoconazole as a satisfactory first-line treatment for keratomycosis (1986) Am J Ophthalmol, 102 (4), pp. 547-548Torres, M.A., Mohamed, J., Cavazos-Adame, H., Martinez, L.A., Topical ketoconazole for fungal keratitis (1985) Am J Ophthalmol, 100 (2), pp. 293-298Komadina, T.G., Wilkes, T.D., Shock, J.P., Ulmer, W.C., Jackson, J., Bradsher, R.W., Treatment of Aspergillus fumigatus keratitis in rabbits with oral and topical ketoconazole (1985) Am J Ophthalmol, 99 (4), pp. 476-479Singh, S.M., Khan, R., Sharma, S., Chatterjee, P.K., Clinical and experimental mycotic corneal ulcer caused by Aspergillus fumigatus and the effect of oral ketoconazole in the treatment (1989) Mycopathologia, 106 (3), pp. 133-141Marangon, F.B., Miller, D., Giaconi, J.A., Alfonso, E.C., In vitro investigation of voriconazole susceptibility for keratitis and endophthalmitis fungal pathogens (2004) Am J Ophthalmol, 137 (5), pp. 820-825Rajasekaran, J., Thomas, P.A., Kalavathy, C.M., Joseph, P.C., Abraham, D.J., Itraconazole therapy for fungal keratitis (1987) Indian J Ophthalmol, 35 (5-6), pp. 157-160Abad, J.C., Foster, C.S., Fungal keratitis (1996) Int Ophthalmol Clin, 36 (3), pp. 1- 15. , ReviewKlotz, S.A., Zahid, M., Bartholomew, W.R., Revera, P.M., Butrus, S., Candida albicans keratitis treated successfully with itraconazole (1996) Cornea, 15 (1), pp. 102-104O'Day, D.M., Foulds, G., Williams, T.E., Robinson, R.D., Allen, R.H., Head, W.S., Ocular uptake of fluconazole following oral administration (1990) Arch Ophthalmol, 108 (7), pp. 1006-1008Thakar, M., Oral fluconazole therapy for keratomycosis (1994) Acta Ophthalmol (Copenh), 72 (6), pp. 765-767Urbak, S.F., Degn, T., Fluconazole in the management of fungal ocular infections (1994) Ophthalmologica, 208 (3), pp. 147-156Mahdy, R.A., Nada, W.M., Wageh, M.M., Kader, M.A., Saleh, M.M., Alswad, M.M., Assessment safety and efficacy of a combination therapy of topical amphotericin B and subconjunctival fluconazole for the treatment of fungal keratitis (2010) Cutan Ocul Toxicol, 29 (3), pp. 193-197Yilmaz, S., Maden, A., Severe fungal keratitis treated with subconjunctival fluconazole (2005) Am J Ophthalmol, 140 (3), pp. 454-458. , Comment in Am J Ophthalmol. 2006;141(4):783author reply 783-4Mahdy, R.A., Nada, W.M., Wageh, M.M., Topical amphotericin B and subconjunctival injection of fluconazole combination therapy versus topical amphotericin B monotherapy in treatment of keratomycosis (2010) J Ocul Pharmacol Ther, 26 (3), pp. 281-285Yee, R.W., Cheng, C.J., Meenakshi, S., Ludden, T.M., Wallace, J.E., Rinaldi, M.G., Ocular penetration and pharmacokinetics of topical fluconazole (1997) Cornea, 16 (1), pp. 64-71. , Comment in Cornea. 1997;16(6):700Avunduk, A.M., Beuerman, R.W., Warnel, E.D., Kaufman, H.E., Greer, D., Comparison of efficacy of topical and oral fluconazole treatment in experimental Aspergillus keratitis (2003) Curr Eye Res, 26 (2), pp. 113-117Dotto, P.F., Rodrigues, L.D., Fernandes, M.L.B., Figueira, B.B.D., Takahashi, W.Y., Carani, J.C., Serracarbassa, P.D., Uso do fluconazol endovenoso no tratamento da endoftalmite fúngica endógena: relato de caso (2005) Arq Bras Oftalmol, 68 (4), pp. 543-546Christmas, N.J., Smiddy, W.E., Vitrectomy and systemic fluconazole for treatment of endogenous fungal endophthalmitis (1996) Ophthalmic Surg Lasers, 27 (12), pp. 1012-1018Wellington, M., Gigliotti, F., Update on antifungal agents (2001) Pediatr Infect Dis J, 20 (10), pp. 993-995Hariprasad, S.M., Mieler, W.F., Lin, T.K., Sponsel, W.E., Graybill, J.R., Voriconazole in the treatment of fungal eye infections: a review of current literature (2008) Br J Ophthalmol, 92 (7), pp. 871-878Herbrecht, R., Denning, D.W., Patterson, T.F., Bennett, J.E., Greene, R.E., Oestmann, J.W., Kern, W.V., Pauw, P.B., Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group.Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis (2002) N Engl J Med, 347 (6), pp. 408- 15. , Comment in N Engl J Med. 2002;347(25):2080-1author reply 2080-1. N Engl J Med. 2002;347(25):2080-1author reply 2080-1. N Engl J Med. 2004;350(9):950-2Freda, R., Use of oral voriconazole as adjunctive treatment of severe cornea fungal infection: case report (2006) Arq Bras Oftalmol, 69 (3), pp. 431-434Hariprasad, S.M., Mieler, W.F., Holz, E.R., Gao, H., Kim, J.E., Chi, J., Prince, R.A., Determination of vitreous, aqueous, and plasma concentration of orally administered voriconazole in humans (2004) Arch Ophthalmol, 122 (1), pp. 42-47Gao, H., Pennesi, M., Shah, K., Qiao, X., Hariprasad, S.M., Mieler, W.F., Safety of intravitreal voriconazole: electroretinographic and histopathologic studies (2003) Trans Am Ophthalmol Soc, 101, pp. 183-189. , discussion 189Anderson, K.L., Mitra, S., Salouti, R., Pham, T.A., Taylor, H.R., Fungal keratitis caused by Paecilomyces lilacinus associated with a retained intracorneal hair (2004) Cornea, 23 (5), pp. 516-521Bunya, V.Y., Hammersmith, K.M., Rapuano, C.J., Ayres, B.D., Cohen, E.J., Topical and oral voriconazole in the treatment of fungal keratitis (2007) Am J Ophthalmol, 143 (1), pp. 151-153Lee, S.J., Lee, J.J., Kim, S.D., Topical and oral voriconazole in the treatment of fungal keratitis (2009) Korean J Ophthalmol, 23 (1), pp. 46-48Nulens, E., Eggink, C., Rijs, A.J., Wesseling, P., Verweij, P.E., Keratitis caused by Scedosporium apiospermum successfully treated with a cornea transplant and voriconazole (2003) J Clin Microbiol, 41 (5), pp. 2261-2264Polizzi, A., Siniscalchi, C., Mastromarino, A., Saccà, S.C., Effect of voriconazole on a corneal abscess caused by fusarium (2004) Acta Ophthalmol Scand, 82 (6), pp. 762-764Al-Badriyeh, D., Neoh, C.F., Stewart, K., Kong, D.C., Clinical utility of voriconazole eye drops in ophthalmic fungal keratitis (2010) Clin Ophthalmol, 4, pp. 391-405Dupuis, A., Tournier, N., Moal, L.G., Venisse, N., Preparation and stability of voriconazole eye drop solution (2009) Antimicrob Agents Chemother, 53 (2), pp. 798-799Clode, A.B., Davis, J.L., Salmon, J., Michau, T.M., Gilger, B.C., Evaluation of concentration of voriconazole in aqueous humor after topical and oral administration in horses (2006) Am J Vet Res, 67 (2), pp. 296-301Prakash, G., Sharma, N., Goel, M., Titiyal, J.S., Vajpayee, R.B., Evaluation of intrastromal injection of voriconazole as a therapeutic adjunctive for the management of deep recalcitrant fungal keratitis (2008) Am J Ophthalmol, 146 (1), pp. 56-59Siatiri, H., Daneshgar, F., Siatiri, N., Khodabande, A., The effects of intrastromal voriconazole injection and topical voriconazole in the treatment of recalcitrant Fusarium keratitis (2011) Cornea, 30 (8), pp. 872-875Sharma, N., Agarwal, P., Sinha, R., Titiyal, J.S., Velpandian, T., Vajpayee, R.B., Evaluation of intrastromal voriconazole injection in recalcitrant deep fungal keratitis: case series (2011) Br J Ophthalmol, 95 (12), pp. 1735-1737Giaconi, J.A., Marangon, F.B., Miller, D., Alfonso, E.C., Voriconazole and fungal keratitis: a report of two treatment failures (2006) J Ocul Pharmacol Ther, 22 (6), pp. 437-439Diekema, D.J., Messer, S.A., Hollis, R.J., Jones, R.N., Pfaller, M.A., Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi (2003) J Clin Microbiol, 41 (8), pp. 3623-3626Johnson, L.B., Kauffman, C.A., Voriconazole: a new triazole antifungal agent (2003) Clin Infect Dis, 36 (5), pp. 630-637Espinel-Ingroff, A., Boyle, K., Sheehan, D.J., In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods: review of the literature (2001) Mycopathologia, 150 (3), pp. 101-115Marco, F., Pfaller, M.A., Messer, S.A., Jones, R.N., Antifungal activity of a new triazole, voriconazole (UK-109,496), compared with three other antifungal agents tested against clinical isolates of filamentous fungi (1998) Med Mycol, 36 (6), pp. 433-436Ullmann, A.J., Cornely, O.A., Burchardt, A., Hachem, R., Kontoyiannis, D.P., Töpelt, K., Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection (2006) Antimicrob Agents Chemother, 50 (2), pp. 658-666Cuenca-Estrella, M., Gomez-Lopez, A., Mellado, E., Buitrago, M.J., Monzon, A., Rodriguez-Tudela, J.L., Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi (2006) Antimicrob Agents Chemother, 50 (3), pp. 917-921Torres, H.A., Hachem, R.Y., Chemaly, R